Keyphrases
Crohn's Disease
100%
Ulcerative Colitis
100%
Biological Treatment
100%
Treatment Patterns
100%
Nationwide Register Study
100%
Crohn's Colitis
80%
Ulcerative Colitis Patient
80%
Number of Patients
40%
IBD Diagnosis
40%
Denmark
20%
Moderate to Severe
20%
Register Study
20%
Severe Disease
20%
National Register
20%
Adalimumab
20%
Infliximab
20%
First Year
20%
Disease Severity
20%
Treatment Choice
20%
Danish National Patient Registry
20%
Increasing Trends
20%
Initiating Treatment
20%
Biological Response Modifiers
20%
Golimumab
20%
Biologic Therapy
20%
Vedolizumab
20%
Nursing and Health Professions
Biological Product
100%
Ulcerative Colitis
100%
Crohn's Disease
100%
Inflammatory Bowel Disease
25%
Practice Guideline
12%
Disease
12%
Disease Severity
12%
Biological Therapy
12%
Infliximab
12%
Golimumab
12%
Adalimumab
12%
Biological Response Modifier
12%
Vedolizumab
12%
Medicine and Dentistry
Crohn's Disease
100%
Ulcerative Colitis
100%
Biological Product
100%
Inflammatory Bowel Disease
25%
Disease
12%
Adalimumab
12%
Infliximab
12%
Disease Severity
12%
Biological Therapy
12%
Patient Registry
12%
Biological Response Modifier
12%
Golimumab
12%
Vedolizumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
100%
Crohn's Disease
100%
Biological Product
100%
Inflammatory Bowel Disease
25%
Disease
12%
Infliximab
12%
Disease Severity
12%
Adalimumab
12%
Biological Response Modifier
12%
Patient Registry
12%
Golimumab
12%
Vedolizumab
12%
Immunology and Microbiology
Crohn's Disease
100%
Ulcerative Colitis
100%
Biological Product
100%
Inflammatory Bowel Disease
25%
Infliximab
12%
Adalimumab
12%
Biological Response Modifier
12%
Golimumab
12%
Vedolizumab
12%